What's happening
This bill requires health insurance policies in New York to cover at least one opioid antagonist and related device, like naloxone.
Why it matters
Expands access to life-saving overdose treatments. By requiring insurance coverage for at least one opioid antagonist and related device, the bill makes these emergency treatments more accessible and affordable for people at risk of opioid overdose and those around them.
Covers broader distribution methods. The bill mandates coverage not only for individuals but also for opioid antagonists prescribed or dispensed via standing orders or collaborative practice agreements, which can allow community organizations, schools, or families to obtain naloxone for use on others—potentially increasing community preparedness for overdoses.
Limits out-of-pocket cost protections. While insurance plans may still apply deductibles and co-insurance, the bill ensures these costs are consistent with other covered benefits, preventing plans from singling out opioid antagonists for higher patient costs and helping to reduce financial barriers.
Allows flexibility in drug selection but protects access. Insurance companies can require prior authorization for non-generic (brand-name) versions, but must always cover at least one FDA-approved opioid antagonist, ensuring there's always at least one accessible, effective option.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Insurers Must Cover Narcan
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to insurance
- Referred to insurance
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
5380
2023-2024 Regular Sessions
IN SENATE
March 3, 2023
Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance
AN ACT to amend the insurance law, in relation to requiring health insurers to provide coverage for opioid antagonists and devices
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 39 to read as follows:
(39) (A) (i) Every policy which provides coverage for prescription drugs shall include coverage for at least one opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid antagonists and devices.
(ii) As used in this paragraph "opioid antagonist and device" means a drug approved by the food and drug administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body. "Opioid antagonist" shall be limited to naloxone and other medications approved by the department of health for such purpose.
(B) The coverage mandated by this paragraph shall include opioid antagonists prescribed or dispensed via standing order or collaborative practice agreement intended for use on patients other than the insured.
(C) Coverage provided under this paragraph may be subject to annual deductibles and co-insurance as deemed appropriate by the superintendent and that are consistent with those imposed on other benefits within a given policy.
§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 7-c to read as follows:
(7-c) (A) (i) Every policy which provides coverage for prescription drugs shall include coverage for at least one opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid antagonists and devices.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD01316-02-3
(ii) As used in this paragraph "opioid antagonist and device" means a drug approved by the food and drug administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body. "Opioid antagonist" shall be limited to naloxone and other medications approved by the department of health for such purpose.
(B) The coverage mandated by this paragraph shall include opioid antagonists prescribed or dispensed via standing order or collaborative practice agreement intended for use on patients other than the insured.
(C) Coverage provided under this paragraph may be subject to annual deductibles and co-insurance as deemed appropriate by the superintendent and that are consistent with those imposed on other benefits within a given policy.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (uu) to read as follows:
(uu) (1) (A) Every policy which provides coverage for prescription drugs shall include coverage for at least one opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid antagonists and devices.
(B) As used in this subsection "opioid antagonist and device" means a drug approved by the food and drug administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body. "Opioid antagonist" shall be limited to naloxone and other medications approved by the department of health for such purpose.
(2) Coverage provided under this subsection may be subject to annual deductibles and co-insurance as deemed appropriate by the superintendent and that are consistent with those imposed on other benefits within a given policy.
§ 4. This act shall take effect on the thirtieth day after it shall have become a law.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to requiring health insurers to provide coverage for opioid antagonists and devices
Purpose
This bill requires health insurers to provide coverage for opioid antag- onists and devices.
Summary of specific provisions
Section 1 amends section 3216 of the insurance law by adding a new para- graph 35.
Section 2 amends subsection 1 of section 3221 of the insurance law by adding a new paragraph 7-c.
Section 3 amends section 4303 of the insurance law is amended by adding a new subsection ss.
Section 4 sets forth the effective date.
Justification
In 2021, the number of deaths from overdoses surged to nearly 107,000 nationally and more than 5,800 in New York. The most immediate concern with addressing this public health crisis is saving lives, and to do that we need to ensure that any New Yorker who want to equip themselves with a lifesaving opioid antagonist, either for themselves or for some- one else, can do that. Currently, under threat of audit from insurance companies, pharmacies are often only selling opioid antagonists to indi- viduals who are purchasing an opioid antagonist for personal use. The deadly consequence of this crackdown is that New Yorkers are often prevented from saving the life of another.
This legislation will require that every policy that provides coverage for prescription drugs shall include coverage for at least one opioid antagonist and device. Critically, the coverage must include opioid antagonists intended for use on patients other than the insured. This bill empowers those seeking to be proactive in protecting the life of someone they believe to be at risk, and helps expand New York State's overdose prevention network.
Legislative history
2021-2022: S6733/A3697 - Died in Insurance
2019-2020: A2773 - Died in Insurance
2017-2018: S8891/A10622 - Died in Insurance/Died in Health
Fiscal implications
Undetermined.
Effective date
This act shall take effect immediately after it shall have become a law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.